NCT01193140 - To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions

Solid Tumor Cancers

Interventions

DRUG

veliparib

Dose orally twice daily for 7 days, consecutively, every cycle

DRUG

Temozolomide

Dose orally once daily for 5 days, consecutively, every cycle

Trial Locations (2)

Site Reference ID/Investigator# 42662, Santa Monica

Site Reference ID/Investigator# 43022, Encinitas